CKD-aP Among Adults on Dialysis in Switzerland

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

401 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-01

Study Completion Date

2023-10-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic Kidney Disease Associated Pruritus (CKD-aP) represents a localized or a generalized skin itch, which is a common symptom occurring in end-stage renal disease and dialysis. The prevalence of CKD-aP in adults on dialysis varies between countries ranging between 20-42%. Swiss data on CKD-aP are unfortunately largely lacking, as Switzerland is so far not part of large registries, such as DOPPS.

The aging population, the increase in diabetes (69% by 2030), the increase in hypertension (60% by 2025) and poly-morbidity will probably lead to a rise in the number of patients on dialysis and subsequent CKD-aP.

CKD-aP is associated with sleep disturbances, compromised quality of life, emotional distress, and increased risks of hospitalization and death. Its management lacks approaches that are supported by strong evidence because its pathogenesis remains poorly understood and may be related to an increase in uremic toxins, skin inflammation. In this context, sweat composition deserves more attention.

Aim of the study The aim of the study is to determine the prevalence of CKD-aP in the population on dialysis, the association between CKD-aP and different electrolytes, and the potential role of the composition of sweat in CKD-aP.

Results will be used for building a CKD-aP symptom management program to improve the quality of care of patients on dialysis and will be incorporated in the nursing continuing education program.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Observational Study of Pruritus Amongst Hemodialysis Patients

NCT00715260

Pruritus Kidney Failure, Chronic Hemodialysis +1 more

UNKNOWN

Effect of Intermittent Hemodialysis on Sleep Apnea Syndrome in End Stage Renal Disease Patients

NCT01860209

Obstructive Sleep Apnea Overhydration End Stage Renal Disease

COMPLETED NA

Treatment of Uremic Pruritus by Olive-omega 3 Ointment

NCT01447693

Uremic Pruritus

UNKNOWN PHASE1/PHASE2

Acupuncture for Pain Management of Hemodialysis Patients

NCT01102816

End-stage Renal Disease Chronic Kidney Disease

TERMINATED NA

AST-120 in Hemodialysis Patients With Uremic Pruritus

NCT04639674

Uremic Pruritus

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Diseases Dialysis Chronic Kidney Diseases Associated Pruritus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CKD-aP

Identification of CKD-aP prevalence and severity among patients on dialysis.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult ≥ 18 years old
* Diagnosed with end-stage renal disease and receiving hemodialysis for at least 6 months
* Able to communicate in French or availability of a French-speaking close relative for translation
* Signed informed consent

* Reporting moderate to severe CKD-aP for the participant considered as a case
* Reporting no or mild CKD-aP for the participant considered as a control Cases and controls will be matched by age-group, sex, and dialysis modality (hemodialysis or peritoneal dialysis).